Results 121 to 130 of about 2,269,258 (384)

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Evolution of a lymphoma with helper T cell characteristics in Sezary syndrome [PDF]

, 1978
EC Lawrence, S Broder, ES Jaffe, Braylan Rc, WO Dobbins, RC Young, Waldmann Ta   +6 more
openalex   +3 more sources

T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma

OncoImmunology, 2018
A reduced immune surveillance due to immune deficiency or treatment with immunosuppressive drugs is associated with a higher risk to develop aggressive Non-Hodgkin's lymphoma (NHL).
Tamara Hilmenyuk, Carla A. Ruckstuhl, Michael Hayoz, Christian Berchtold, Jean-Marc Nuoffer, Shyam Solanki, Hector C. Keun, Paul A. Beavis, Carsten Riether, Adrian F. Ochsenbein   +9 more
doaj   +1 more source

Chidamide in the treatment of peripheral T-cell lymphoma

OncoTargets and Therapy, 2017
Mature T-cell lymphomas are aggressive malignancies. Treatment outcome is poor with conventional chemotherapy. They are about twice as common in Asia as compared with other non-Asian countries.
T. Chan, E. Tse, Y. Kwong
semanticscholar   +1 more source

Phenformin, but not metformin, delays development of T-cell acute lymphoblastic leukemia/lymphoma via cell-autonomous AMPK activation [PDF]

, 2019
Summary: AMPK acts downstream of the tumor suppressor LKB1, yet its role in cancer has been controversial. AMPK is activated by biguanides, such as metformin and phenformin, and metformin use in diabetics has been associated with reduced cancer risk ...
Atrih, Abdelmadjid, Cantrell, Doreen, Dandapani, Madhumita, Foretz, Marc, Grzes, Katarzyna, Hardie, D Grahame, Hardie, D. Grahame, Lamont, Douglas, Russell, Fiona, Vara-Ciruelos, Diana, Viollet, Benoit   +10 more
core   +3 more sources

Biological and technical complexities in analyzing extracellular vesicle immune interactions in B‐cell malignancies

FEBS Letters, EarlyView.
Daniel Bachurski, Michael Hallek
wiley   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

Molecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn, Michael Peled   +10 more
wiley   +1 more source

Sinonasal NK/T-Cell Lymphoma with Upper Gastrointestinal Bleeding: A Case Report

Kaohsiung Journal of Medical Sciences, 2003
Natural killer (NK)/T-cell lymphoma is the most common malignant lymphoma among sinonasal lymphomas. Diagnosis is difficult and prognosis is poor. Herein, we report the case of a 22-year-old male patient with sinonasal NK/T-cell lymphoma who first ...
Kuan-Jung Huang, Ling-Feng Wang, Ka-Wo Lee, Kuen-Yao Ho, Wen-Rei Kuo   +4 more
doaj   +1 more source

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.

Blood, 2015
Early-stage cutaneous T-cell lymphoma (CTCL) is a skin-limited lymphoma with no cure aside from stem cell transplantation. Twelve patients with stage IA-IIA CTCL were treated in a phase 1 trial of 0.03% and 0.06% topical resiquimod gel, a Toll-like ...
A. Rook, J. Gelfand, M. Wysocka, A. Troxel, B. Benoit, C. Surber, R. Elenitsas, M. Buchanan, Deborah Leahy, R. Watanabe, I. Kirsch, Ellen J. Kim, R. Clark   +12 more
semanticscholar   +1 more source

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Journal of Clinical Oncology, 2020
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed best ...
L. Nastoupil, M. Jain, Lei Feng, J. Spiegel, A. Ghobadi, Yi Lin, S. Dahiya, M. Lunning, L. Lekakis, P. Reagan, O. Oluwole, J. Mcguirk, A. Deol, A. Sehgal, A. Goy, B. Hill, K. Vu, C. Andreadis, J. Muñoz, J. Westin, J. Chavez, A. Cashen, N. Bennani, A. Rapoport, J. Vose, D. Miklos, S. Neelapu, F. Locke   +27 more
semanticscholar   +1 more source